Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Alexander Dabrowiecki

Vascular & Interventional Radiology Springfield, OR Medical Doctor

NPI 1538492442 CMS profile 8801804

1200 Gateway Loop, 1200, Springfield, OR 97477

Open in the dashboard

General payments

$9,786

61 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Dabrowiecki of Springfield, OR is reported in the CMS Open Payments database as having received $9,786 across 61 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,462 28
2024 General $604 10
2023 General $839 10
2022 General $670 9
2021 General $130 1
2020 General $82 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Dabrowiecki
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Alexander Dabrowiecki were reported at $7,462. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Alexander Dabrowiecki Vascular & Interventional Radiology median Middle half National median
2019 $0 $422 $125–$1,555 $163
2020 $82 $200 $68–$652 $114
2021 $130 $280 $99–$866 $132
2022 $670 $433 $137–$1,497 $149
2023 $839 $506 $152–$2,019 $160
2024 $604 $556 $175–$1,930 $164
2025 $7,462 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AngioDynamics, Inc. $6,000 1 payment
  2. Boston Scientific Corporation $710 13 payments
  3. Stryker Corporation $454 5 payments
  4. Inari Medical, Inc. $398 5 payments
  5. Globus Medical, Inc. $365 9 payments
  6. Abbott Laboratories $346 7 payments
  7. Endologix, Inc. $334 1 payment
  8. Terumo Medical Corporation $319 3 payments
  9. Penumbra, Inc. $234 2 payments
  10. Nevro Corp. $138 4 payments
  11. Other $488 11 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Long term medical supply or device loan $6,000 1 payment
  2. Food and Beverage $3,062 55 payments
  3. Travel and Lodging $724 5 payments
Products named General payments · program years 2020–2025
  1. Auryon Laser System 100-120 Vac $6,000 1 payment
  2. SPINEJACK $432 4 payments
  3. FLOWTRIEVER CATHETER, S $398 5 payments
  4. CT THROMBECTOMY SYSTEM KIT $398 5 payments
  5. Senza $365 9 payments
  6. ENDOCROSS Device $334 1 payment
  7. Torus Stent Graft System $334 1 payment
  8. General - Therapies $331 3 payments
  9. RotarexS 6 F x 135 cm $217 4 payments
  10. ESPRIT $187 1 payment
  11. Other $1,505 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 211 billing codes

Paid by Medicare

$138,354

Of which drugs: $365

Medicare patients

1,918

Average age 74

Services billed

7,173

1,086 women, 832 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 30%
Chronic kidney disease 30%
Depression 29%
Heart failure 26%
Ischemic heart disease 25%
Atrial fibrillation 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 44 3,778 $343

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

61 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record